地高辛临床获益与风险的研究进展  

Progress in Applications of Digoxin about Clinical Benefits and Risks

作　　者：王锦溪[1] 李虹伟[1] 

机构地区：[1]首都医科大学附属北京友谊医院心血管中心,北京市100050

出　　处：《中国全科医学》2013年第16期1927-1929,共3页Chinese General Practice

摘　　要：作为最古老的心血管药物,地高辛现今仍广泛用于临床治疗慢性心功能不全(CHF)及房颤(AF)。经典临床试验的后续分析对地高辛获益与风险进行再次论证,提出地高辛的临床应用需要重新审视。现就地高辛在CHF及AF患者中的疗效观察及风险评估进行综述,并且介绍地高辛在临床应用方面的最新进展。As the oldest compound in cardiovascular medicine, Digoxin is widely used in clinical practice for treatment of chronic heart failure （CHF） and atrial fibrillation （AF） nowadays. The post hoc analysis of classic clinical trials demon- strates that the benefits and risks of Digoxin remain controversial and the clinical practice should be reassessed. This review focu- ses on the evidence of benefits and risks of Digoxin therapy in patients with CHF and AF, and presents the latest progress in clini- cal application of Digoxin.

关 键 词：地高辛 慢性心功能不全 心房颤动 

分 类 号：R972[医药卫生—药品]